Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome

INTRODUCTION: Alport syndrome is a rare genetic disorder that affects as many as 60,000 persons in the USA and a total of 103,000 persons (<5 per 10,000) in the European Union [1, 2]. It is the second most common inherited cause of kidney failure and is characterized by progressive loss of kidney...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Am J Nephrol
Main Authors: Chertow, Glenn M., Appel, Gerald B., Andreoli, Sharon, Bangalore, Sripal, Block, Geoffrey A., Chapman, Arlene B., Chin, Melanie P., Gibson, Keisha L., Goldsberry, Angie, Iijima, Kazumoto, Inker, Lesley A., Knebelmann, Bertrand, Mariani, Laura H., Meyer, Colin J., Nozu, Kandai, O'Grady, Megan, Silva, Arnold L., Stenvinkel, Peter, Torra, Roser, Warady, Bradley A., Pergola, Pablo E.
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger AG 2021
Assuntos:
Patient-Oriented, Translational Research: Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8220919/
https://ncbi.nlm.nih.gov/pubmed/33789284
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000513777
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados